Protocol Ledger

NCT07516951 · Phase II · RECRUITING

A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

Interventional Phase II clinical trial protocol NCT07516951 sponsored by Chiesi Farmaceutici S.p.A in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-07-08 Enrollment: 240 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07516951
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07516951
Protocol FieldVerified Registry Value
NCT IdentifierNCT07516951
Consolidated Lead SponsorChiesi Farmaceutici S.p.A
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment240 participants (ESTIMATED)
Registered Start Date2026-07-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07516951
Hospital Research SiteLocationSite Profile
Inje University Haeundae Paik HospitalBusan, South KoreaOpen Hospital Dossier ->
Chonnam National University HospitalGwangju, South KoreaOpen Hospital Dossier ->
Kyung Hee University HospitalSeoul, South KoreaOpen Hospital Dossier ->
Korea University Anam HospitalSeoul, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI